New incretin receptor agonist significantly reduces weight and cholesterol levels

The novel incretin receptor agonist pemvidutide causes significant weight loss in obese individuals. In addition, the drug has a beneficial cardiometabolic effect, reducing blood pressure, total cholesterol, and triglycerides.

Scientists from Weill Cornell Medical College assessed the effectiveness and safety of the new incretin receptor agonist pemvidutide. Results from the phase II MOMENTUM study, presented during the annual meeting of the European Association for Research in Diabetes (EASD), were published by Medscape.

Pemvidutide is a long-acting dual glucagon-like peptide-1 (GLP-1) and glucagon agonist. At 24 weeks into the study, the average weight loss among participants who received 2.4 mg pemvidutide was 10.7%. In the 1.8 mg pemvidutide group, the reduction was 9.4%. Among participants who took 1.2 mg of the drug, weight decreased by an average of 7.3%. The proportion of patients whose weight decreased by at least 5% was 84.6, 66.7 and 66.7%, respectively. In the placebo group, weight decreased by 5% in 25% of participants. Waist circumference has also decreased.

In addition, taking the drug led to a significant decrease in the level of total cholesterol and triglycerides. Systolic blood pressure decreased by 5.5 mm Hg, and diastolic blood pressure decreased by 1.8 mm Hg. while taking 2.4 mg of the drug.

It is important to note that, as with all drugs in this class, gastrointestinal side effects, including vomiting, have been observed with pemvidutide.

The study included 320 overweight and obese patients with at least one obesity-related comorbidity. Participants received 1.2 mg, 1.8 mg, or 2.4 mg pemvidutide or placebo for 48 weeks.

Full results from the MOMENTUM study will be presented in the fourth quarter of 2023. The drug is being developed for the treatment of obesity and non-alcoholic steatohepatitis.

Source link